GlassScriptPhysician profile
Kelsey L Able
NPI 1376806588
$2,706.84
in general payments reported to CMS, 2019-2025
28 companies · $1,452 in 2025
The $1,452 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21.30 · 2020: $41.03 · 2021: $124 · 2022: $111 · 2023: $326 · 2024: $632 · 2025: $1,452.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,335 · Education: $74.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,334.98 |
| Education | $74.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $703.51 | 2020-2025 | Tremfya, Stelara |
| Abbvie INC. | $650.58 | 2022-2025 | Rinvoq, Skyrizi, Linzess |
| Medtronic, INC. | $204.40 | 2025 | Interstim |
| Ardelyx, INC. | $151.76 | 2022-2025 | Ibsrela |
| Lilly USA, LLC | $133.39 | 2024-2025 | Omvoh |
| Pfizer INC. | $110.06 | 2023-2025 | |
| Boston Scientific Corporation | $109.57 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $85.40 | 2022-2023 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $57.97 | 2020-2025 | Eohilia, Entyvio |
| Celgene Corporation | $50.44 | 2021-2023 | Zeposia |
| Qol Medical, LLC | $48.34 | 2024-2025 | Sucraid, Sucraid |
| Enterra Medical, INC. | $40.11 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.45 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $36.83 | 2025 | Voquezna |
| Ucb, INC. | $35.52 | 2024 | Cimzia |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Micro-Tech Endoscopy USA, INC. | $26.29 | 2024-2025 | Riteclip, Guidewires |
| Novo Nordisk INC | $25.34 | 2025 | Wegovy |
| Intercept Pharmaceuticals, INC. | $23.92 | 2025 | |
| Genzyme Corporation | $23.59 | 2025 | |
| Celltrion USA INC. | $22.21 | 2024 | Zymfentra |
| Fresenius Kabi USA, LLC | $21.99 | 2023 | |
| Organon LLC | $20.81 | 2023 | Hadlima, Renflexis |
| Braintree Laboratories, INC. | $20.23 | 2024 | Suflave, Sutab |
| Janssen Scientific Affairs, LLC | $19.86 | 2025 | Tremfya |
| Madrigal Pharmaceuticals | $19.05 | 2025 | Rezdiffra |
| Stryker Corporation | $17.87 | 2023 | Neptune |
| Endogastric Solutions, INC | $10.35 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$17,623.22 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelsey Able listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.